News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Oral Hepatitis C Regimen Looks Competitive: Study


4/23/2013 7:57:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

A combination of three experimental Bristol-Myers Squibb hepatitis C drugs appeared to be highly effective, according to data from a mid-stage clinical trial, keeping the company in the race for developing an all-oral treatment regimen for the serious liver disease. The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study. Current treatment regimens for the disease still include the older, difficult-to-tolerate drugs interferon and ribavirin and are typically taken for either 24 weeks or 48 weeks. When used with newer drugs, they have cure rates as high as about 80 percent. Several companies are developing hepatitis C regimens that do not include interferon - which is given intravenously and often causes miserable flu-like symptoms - while also pursuing much shorter treatment durations.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at BusinessWeek
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES